OpiCalc

989 Clinical Tools

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk Score CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

MAGIC aGvHD Biomarker Score

MAGIC Biomarker Staging: Predicting Non-Relapse Mortality (NRM) using serum concentrations of ST2 and Reg3α. Note: Formal MAGIC calculation requires specific laboratory standardization.

ST2 (ng/mL)

Marker of systemic inflammation

Reg3α (ng/mL)

Marker of GI crypt damage

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Prognostic assessment of patients at the onset of Grade I–IV acute Graft-versus-Host Disease (aGvHD).

To predict the probability of Non-Relapse Mortality (NRM) independent of clinical severity.

Identifying "high-risk" patients who may benefit from augmented first-line or early second-line therapy.

Patient Population

Adult and pediatric patients following allogeneic hematopoietic cell transplantation (alloHCT) who develop clinical aGvHD.

Section 2

Formula & Logic

Primary MAGIC Biomarkers

Biomarker	Significance
ST2	Marker of systemic inflammation and endothelial distress; predictor of steroid-refractory GvHD.
Reg3α	Marker of intestinal crypt damage; specific for gastrointestinal GvHD.

Ann Arbor Staging (Biomarker-based)

Stage	Risk Level	6-month NRM (%)
1	Low Risk	5 - 10%
2	Intermediate Risk	20 - 25%
3	High Risk	40 - 50%

Section 3

Pearls/Pitfalls

Biomarkers vs. Symptoms

Biomarkers often reveal the biological severity of aGvHD before the full clinical phenotype emerges. For example, a patient with mild (Stage 1) skin and GI symptoms but High-Risk MAGIC biomarkers has a significantly higher hazard of death than a patient with severe symptoms but Low-Risk biomarkers.

Section 4

Evidence Appraisal

Primary Score

A biomarker-based algorithm for the diagnosis and risk stratification of acute graft-versus-host disease.

Harris AC et al. • JCI Insight. 2017;2(3):e91530.

View Source

Section 5

Literature

Consortium

Developed by the Mount Sinai Acute GvHD International Consortium (MAGIC), a group of over 20 transplant centers worldwide dedicated to improving aGvHD monitoring.

Last Comprehensive Review: 2026

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Prognostic assessment of patients at the onset of Grade I–IV acute Graft-versus-Host Disease (aGvHD).

To predict the probability of Non-Relapse Mortality (NRM) independent of clinical severity.

Identifying "high-risk" patients who may benefit from augmented first-line or early second-line therapy.

Patient Population

Adult and pediatric patients following allogeneic hematopoietic cell transplantation (alloHCT) who develop clinical aGvHD.

Section 2

Formula & Logic

Primary MAGIC Biomarkers

Biomarker	Significance
ST2	Marker of systemic inflammation and endothelial distress; predictor of steroid-refractory GvHD.
Reg3α	Marker of intestinal crypt damage; specific for gastrointestinal GvHD.

Ann Arbor Staging (Biomarker-based)

Stage	Risk Level	6-month NRM (%)
1	Low Risk	5 - 10%
2	Intermediate Risk	20 - 25%
3	High Risk	40 - 50%

Section 3

Pearls/Pitfalls

Biomarkers vs. Symptoms

Section 4

Evidence Appraisal

Primary Score

A biomarker-based algorithm for the diagnosis and risk stratification of acute graft-versus-host disease.

Harris AC et al. • JCI Insight. 2017;2(3):e91530.

View Source

Section 5

Literature

Consortium

Developed by the Mount Sinai Acute GvHD International Consortium (MAGIC), a group of over 20 transplant centers worldwide dedicated to improving aGvHD monitoring.

Last Comprehensive Review: 2026

Related Hematology Tools

Binet / Rai Staging

iwCLL Response Criteria

Revised Response Criteria

PCNSL MSKCC Score

ISS

R-ISS

IMWG Response Criteria

MRD Assessment Threshold Interpreter

mSMART 3.0

SLiM-CRAB Criteria

Have feedback about this calculator?Let us know.

MAGIC aGvHD Biomarker Score

MAGIC Biomarker Staging: Predicting Non-Relapse Mortality (NRM) using serum concentrations of ST2 and Reg3α. Note: Formal MAGIC calculation requires specific laboratory standardization.

ST2 (ng/mL)

Marker of systemic inflammation

Reg3α (ng/mL)

Marker of GI crypt damage

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Prognostic assessment of patients at the onset of Grade I–IV acute Graft-versus-Host Disease (aGvHD).

To predict the probability of Non-Relapse Mortality (NRM) independent of clinical severity.

Identifying "high-risk" patients who may benefit from augmented first-line or early second-line therapy.

Patient Population

Adult and pediatric patients following allogeneic hematopoietic cell transplantation (alloHCT) who develop clinical aGvHD.

Section 2

Formula & Logic

Primary MAGIC Biomarkers

Biomarker	Significance
ST2	Marker of systemic inflammation and endothelial distress; predictor of steroid-refractory GvHD.
Reg3α	Marker of intestinal crypt damage; specific for gastrointestinal GvHD.

Ann Arbor Staging (Biomarker-based)

Stage	Risk Level	6-month NRM (%)
1	Low Risk	5 - 10%
2	Intermediate Risk	20 - 25%
3	High Risk	40 - 50%

Section 3

Pearls/Pitfalls

Biomarkers vs. Symptoms

Section 4

Evidence Appraisal

Primary Score

A biomarker-based algorithm for the diagnosis and risk stratification of acute graft-versus-host disease.

Harris AC et al. • JCI Insight. 2017;2(3):e91530.

View Source

Section 5

Literature

Consortium

Developed by the Mount Sinai Acute GvHD International Consortium (MAGIC), a group of over 20 transplant centers worldwide dedicated to improving aGvHD monitoring.

Last Comprehensive Review: 2026

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Prognostic assessment of patients at the onset of Grade I–IV acute Graft-versus-Host Disease (aGvHD).

To predict the probability of Non-Relapse Mortality (NRM) independent of clinical severity.

Identifying "high-risk" patients who may benefit from augmented first-line or early second-line therapy.

Patient Population

Adult and pediatric patients following allogeneic hematopoietic cell transplantation (alloHCT) who develop clinical aGvHD.

Section 2

Formula & Logic

Primary MAGIC Biomarkers

Biomarker	Significance
ST2	Marker of systemic inflammation and endothelial distress; predictor of steroid-refractory GvHD.
Reg3α	Marker of intestinal crypt damage; specific for gastrointestinal GvHD.

Ann Arbor Staging (Biomarker-based)

Stage	Risk Level	6-month NRM (%)
1	Low Risk	5 - 10%
2	Intermediate Risk	20 - 25%
3	High Risk	40 - 50%

Section 3

Pearls/Pitfalls

Biomarkers vs. Symptoms

Section 4

Evidence Appraisal

Primary Score

A biomarker-based algorithm for the diagnosis and risk stratification of acute graft-versus-host disease.

Harris AC et al. • JCI Insight. 2017;2(3):e91530.

View Source

Section 5

Literature

Consortium

Developed by the Mount Sinai Acute GvHD International Consortium (MAGIC), a group of over 20 transplant centers worldwide dedicated to improving aGvHD monitoring.

Last Comprehensive Review: 2026

Related Hematology Tools

Binet / Rai Staging

iwCLL Response Criteria

Revised Response Criteria

PCNSL MSKCC Score

ISS

R-ISS

IMWG Response Criteria

MRD Assessment Threshold Interpreter

mSMART 3.0

SLiM-CRAB Criteria

Have feedback about this calculator?Let us know.